Here is the new drug to reduce the risk

new protein”sponge“It could be the key to reducing the risk of heart attacks, as it will be able to cleanse the arteries of the heart of excess cholesterol while avoiding the formation of dangerous plaques. The research states. Aegis II, promoted Harvard Medical School from Boston in the US who studies apolipoprotein apoA-I: a type of sponge that absorbs fats that come in contact with it, including those that can clog blood vessels.

Study: 20,000 participants

The study aims to recruit about 20,000 participants across 1,035 centers around the world. Among these, Irccs MultiMedica in Sesto San Giovanni, near Milan, which registered its first patient. Phase 3 clinical trials will test efficacy and safetycore protein In patients with acute coronary syndromes, such as myocardial infarction. The primary goal of the work is specifically to “monitor whether this treatment is able to reduce the risk of further cardiovascular events in the first 90 days after a heart attack, which is the period of greatest weakness,” emphasizes Roberto Pedretti, director of the cardiovascular division at Irccs. , who applied the research protocol to the first patient registered by the institute.

Italy has 130,000 heart attacks each year

In fact, about 130,000 patients in Italy have a heart attack each year and 20% have a new event within 12 months. This is why prevention is so important. “Mrs. Giovanna (invented name) was discharged from the hospital and came home in perfect condition,” Pedretti explains. “She was hospitalized with a heart attack and, in addition to all the usual treatments, was the first patient to enter this study on apoA-I, who His protocol provides for four intravenous injections over a period of a few weeks and follow-up for one year. Giovanna will now be followed up periodically by our center to monitor clinical progress after some time. Other heart attack patients can be treated by us with this very innovative approach.”

How does the new protein work?

This is an innovative approach: “While current drugs work by reducing cholesterol synthesis and preventing the formation of new buildups, this treatment is more ambitious and has not been achieved before: attacking plaque already present in the arteries,” explains Giuseppe Ambrosio, study coordinator for Italy and deputy scientific director of Irccs MultiMedica. . How? Fats do not dissolve in water, but rather circulate in the blood because they are included in certain proteins called lipoproteins. This is why they are dangerous to the circulatory system because they can create plaques. “By injecting into the blood, a precursor of an Hdl lipoprotein, a lipoprotein without a lipoprotein called apolipoprotein A1, This attracts excess cholesterol to itselfExplains Ambrosio, who assures us that “it is a completely new approach, which we hope will contribute to the reduction of acute events in those who have a heart attack. The preliminary results are very encouraging ».

Diet and meat yes or no? Complaint: “Vegan hurts.” Here is the damage to the metabolism of those who give up animal proteins

innovative approach

in conclusionAim of the study is to confirm the hypothesis that an early reduction in cholesterol present in atherosclerotic plaques, through intravenous administration of lipoprotein A1, is consistent with a reduced likelihood of other cardiovascular problems: “Achieving a similar goal, would allow us to determine the shadow of a landmark in” The field of ‘HDL pharmacology’ is yet uncertain» comments Alberico Catapano, Director of the Center for Irccs MultiMedica dyslipidemia and Professor of Pharmacology at the University of Milan.

Leave a Comment